Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13123230 | 0.94 | DHFR (0.51) | DHFR | |
| SCHEMBL9916086 | 0.93 | DHFR (0.54) | DHFR | |
| SCHEMBL9916149 | 0.93 | DHFR (0.54) | DHFR | |
| Ch-1504 L-Isomer SCHEMBL1052620 | 0.89 | DHFR (0.65) | DHFR | |
| Ch-1504 L-Isomer SCHEMBL29430181 | 0.89 | DHFR (0.65) | DHFR | |
| Ch-1504 SCHEMBL29430185 | 0.89 | DHFR (0.65) | DHFR | |
| Ch-1504 SCHEMBL7281 | 0.89 | DHFR (0.65) | DHFR | |
| SCHEMBL1128102 | 0.87 | DHFR (0.53) | DHFR | |
| SCHEMBL6974948 | 0.87 | DHFR (0.53) | DHFR | |
| SCHEMBL6974971 | 0.84 | DHFR (0.56) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253719-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | CHELSEA THERAPEUTICS, INC. | 2009-10-08 | — | — | US | claimed |
| US-20140142109-A1 | ANTIFOLATE COMBINATIONS | CHELSEA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8658652-B2 | Antifolate combinations | CHELSEA THERAPEUTICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2012078708-A1 | COMBINATION COMPRISING METHOTREXATE AND AN ANTIFOLATE COMPOUND | CHELSEA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142692-A1 | ANTIFOLATE COMBINATIONS | CHELSEA THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| EP-2300441-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | Chelsea Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2282740-A1 | ANTIFOLATE COMPOSITIONS | Chelsea Therapeutics, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009126637-A1 | ANTIFOLATE COMPOSITIONS | CHELSEA THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126639-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253720-A1 | ANTIFOLATE COMPOSITIONS | CHELSEA THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253719-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | CHELSEA THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142109-A1 | ANTIFOLATE COMBINATIONS | DHFR, MTX1, MTHFD1 | DHFR 1/4885 |
| US-20120142692-A1 | ANTIFOLATE COMBINATIONS | DHFR, MTX1, MTHFD1 | DHFR 1/4885 |
| US-20090253720-A1 | ANTIFOLATE COMPOSITIONS | FDFT1, SLC19A1, FIBP | DHFR 4/4885 |
| US-20090253719-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | SLC7A1, SLC10A1, SLC10A6 | DHFR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.